FDA Speeds Up Approvals for Lab Test Devices
Published Date: 5/1/2026
Notice
Summary
The FDA wants to make it easier for some medical devices used in toxicology tests by removing the need for a special pre-approval process. This change could speed up how these devices get to market and might save money for makers and users. The FDA is asking for your thoughts by June 30, 2026, before making a final decision.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
510(k) Exemption for Toxicology Tests
FDA intends to exempt certain Class II clinical toxicology test system devices from the 510(k) premarket notification when they are intended for Federal drug testing programs. If finalized, regulated industry will no longer need to submit 510(k) submissions for those listed devices, reducing the time and private costs businesses now spend preparing 510(k)s.
Exemptions Subject to Limits and Labeling
Even if exempted from 510(k), these devices remain subject to the general limitations in 21 CFR 862.9 and the proposed partial limitation that the test system be intended for employment and insurance testing and include labeling stating it is intended solely for employment and insurance testing. Manufacturers must still submit a 510(k) before marketing if a device exceeds those limitations.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2026-08496 — Agency Information Collection Activities: Proposed Collection; Comment Request
SAMHSA is updating the annual report form for the PATH program, which helps states and territories support people transitioning from homelessness. This change affects all PATH grant recipients and aims to make reporting clearer and easier, without adding extra costs or time. Comments are open now, so stakeholders can share ideas before the January 31 deadline for submitting reports.
Next: 2026-08500 — Combined Notice of Filings #1
The Federal Energy Regulatory Commission got a bunch of new filings from energy companies like solar farms and power plants. These filings include status updates, tariff changes, and complaints that could affect energy rates and operations soon. If you’re involved in energy or just curious, keep an eye on deadlines for comments mostly due by mid-May 2026.